Loading...
Loading...
KZIA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 2,898.3K |
| Gross Profit | -2,898.3K |
| Operating Expense | -3,217.6K |
| Operating I/L | 7,700.6K |
| Other Income/Expense | -4,444.2K |
| Interest Income | 0.0K |
| Pretax | 3,256.3K |
| Income Tax Expense | 149.1K |
| Net Income/Loss | 3,107.2K |
Kazia Therapeutics Limited is an oncology-focused biotechnology company that develops anti-cancer drugs. Its lead development candidate, Paxalisib, is a brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, aimed at treating glioblastoma. The company is also working on EVT801, an investigational new drug for various forms of cancer. Kazia Therapeutics Limited, formerly known as Novogen Limited, generates revenue through the development and potential commercialization of these innovative therapies for cancer treatment.
